

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding the role of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-239/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-239" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding the role of glucagon-like peptide 1" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding the role of glucagon-like peptide 1.">
            <meta name="og:description" content="Read the latest article version by Josh Reed, Stephen C. Bain, Venkateswarlu Kanamarlapudi, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="22653">
            <meta name="article-id" content="20602">
            <meta name="dc.title" content="Recent advances in understanding the role of glucagon-like peptide 1">
            <meta name="dc.description" content="The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1&ndash;based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson&rsquo;s disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic&ndash;based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases.">
            <meta name="dc.subject" content="GLP-1, Type 2 diabetes, incretin, GLP-1R">
            <meta name="dc.creator" content="Reed, Josh">
            <meta name="dc.creator" content="Bain, Stephen C.">
            <meta name="dc.creator" content="Kanamarlapudi, Venkateswarlu">
            <meta name="dc.date" content="2020/04/06">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.20602.1">
            <meta name="dc.source" content="F1000Research 2020 9:239">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="GLP-1">
            <meta name="prism.keyword" content="Type 2 diabetes">
            <meta name="prism.keyword" content="incretin">
            <meta name="prism.keyword" content="GLP-1R">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/04/06">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="239">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.20602.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-239">
            <meta name="citation_title" content="Recent advances in understanding the role of glucagon-like peptide 1">
            <meta name="citation_abstract" content="The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1&ndash;based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson&rsquo;s disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic&ndash;based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases.">
            <meta name="citation_description" content="The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1&ndash;based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson&rsquo;s disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic&ndash;based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases.">
            <meta name="citation_keywords" content="GLP-1, Type 2 diabetes, incretin, GLP-1R">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Josh Reed">
            <meta name="citation_author_institution" content="Institute of Life Science, Medical School, Swansea University, Swansea, Wales, SA2 8PP, UK">
            <meta name="citation_author" content="Stephen C. Bain">
            <meta name="citation_author_institution" content="Institute of Life Science, Medical School, Swansea University, Swansea, Wales, SA2 8PP, UK">
            <meta name="citation_author" content="Venkateswarlu Kanamarlapudi">
            <meta name="citation_author_institution" content="Institute of Life Science, Medical School, Swansea University, Swansea, Wales, SA2 8PP, UK">
            <meta name="citation_publication_date" content="2020/04/06">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="239">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.20602.1">
            <meta name="citation_firstpage" content="239">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-239/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-239.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=22653 /> <input type=hidden id=articleId name=articleId value=20602 /> <input type=hidden id=xmlUrl value="/articles/9-239/v1/xml"/> <input type=hidden id=xmlFileName value="-9-239-v1.xml"> <input type=hidden id=article_uuid value=83ae52c5-8505-438c-aac2-48d1c1d8abcd /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding the role of glucagon-like peptide 1"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.20602.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.20602.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-239"
  },
  "headline": "Recent advances in understanding the role of glucagon-like peptide 1",
  "datePublished": "2020-04-06T18:31:05",
  "dateModified": "2020-04-06T18:31:05",
  "author": [
    {
      "@type": "Person",
      "name": "Josh Reed"
    },    {
      "@type": "Person",
      "name": "Stephen C. Bain"
    },    {
      "@type": "Person",
      "name": "Venkateswarlu Kanamarlapudi"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1&ndash;based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson&rsquo;s disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic&ndash;based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-239",
            "name": "Recent advances in understanding the role of glucagon-like peptide..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding the role of glucagon-like peptide... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=22653 data-id=20602 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20602.1" data-recommended="" data-doi="10.12688/f1000research.20602.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-239/v1/pdf?article_uuid=83ae52c5-8505-438c-aac2-48d1c1d8abcd" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-20602-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-20602-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-20602-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Reed J, Bain SC and Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):239 (<a class=new-orange href="https://doi.org/10.12688/f1000research.20602.1" target=_blank>https://doi.org/10.12688/f1000research.20602.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-20602-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=20602 id=track-article-signin-20602 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20602?target=/articles/9-239">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22653 /> <input name=articleId type=hidden value=20602 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding the role of glucagon-like peptide 1</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Josh Reed,&nbsp;</span><span class="">Stephen C. Bain,&nbsp;</span><span class=""><a href="mailto:k.venkateswarlu@swansea.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Venkateswarlu Kanamarlapudi</span></a><a href="https://orcid.org/0000-0002-8739-1483" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8739-1483</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Josh Reed,&nbsp;</span><span class="">Stephen C. Bain,&nbsp;</span><span class=""><a href="mailto:k.venkateswarlu@swansea.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Venkateswarlu Kanamarlapudi</span></a><a href="http://orcid.org/0000-0002-8739-1483" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8739-1483</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 06 Apr 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.20602.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Institute of Life Science, Medical School, Swansea University, Swansea, Wales, SA2 8PP, UK<br/> <p> <div class=margin-bottom> Josh Reed <br/> <span>Roles: </span> Conceptualization, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Stephen C. Bain <br/> <span>Roles: </span> Funding Acquisition, Writing – Review & Editing </div> <div class=margin-bottom> Venkateswarlu Kanamarlapudi <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=65693-61617></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=65694-61618></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action. Although owing to its short half-life exogenous GLP-1 has no use therapeutically, GLP-1 mimetics, which have a much longer half-life than native GLP-1, have proven to be effective for T2D treatment since they prolong the incretin effect in patients. These GLP-1 mimetics are a desirable therapeutic option for T2D since they do not provoke hypoglycaemia or weight gain and have simple modes of administration and monitoring. Additionally, over more recent years, GLP-1 action has been found to mediate systemic physiological beneficial effects and this has high clinical relevance due to the post-diagnosis complications of T2D. Indeed, recent studies have found that certain GLP-1 analogue therapies improve the cardiovascular outcomes for people with diabetes. Furthermore, GLP-1–based therapies may enable new therapeutic strategies for diseases that can also arise independently of the clinical manifestation of T2D, such as dementia and Parkinson’s disease. GLP-1 functions by binding to its receptor (GLP-1R), which expresses mainly in pancreatic islet beta cells. A better understanding of the mechanisms and signalling pathways by which acute and chronic GLP-1R activation alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 mimetic–based therapies, which improve prognosis to a greater extent than current therapies for an array of diseases. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> GLP-1, Type 2 diabetes, incretin, GLP-1R </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Venkateswarlu Kanamarlapudi (<a href="mailto:k.venkateswarlu@swansea.ac.uk">k.venkateswarlu@swansea.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Venkateswarlu Kanamarlapudi </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The authors declared that Biotechnology and Biological Sciences Research Council (BBSRC) UK (BB/F017596/1) and Knowledge Economy Skills Scholarship (KESS) UK PhD studentship grants were involved in supporting this work. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Reed J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Reed J, Bain SC and Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):239 (<a href="https://doi.org/10.12688/f1000research.20602.1" target=_blank>https://doi.org/10.12688/f1000research.20602.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 06 Apr 2020, <b>9</b>(F1000 Faculty Rev):239 (<a href="https://doi.org/10.12688/f1000research.20602.1" target=_blank>https://doi.org/10.12688/f1000research.20602.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 06 Apr 2020, <b>9</b>(F1000 Faculty Rev):239 (<a href="https://doi.org/10.12688/f1000research.20602.1" target=_blank>https://doi.org/10.12688/f1000research.20602.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d20143e156>Introduction</h2><p class="" id=d20143e159>Glucagon-like peptide 1 (GLP-1) was initially identified as a gut-derived incretin hormone that augments insulin secretion in a glucose-dependent manner from pancreatic islet beta cells during the postprandial period<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Subsequent research discovered that GLP-1 also lowered glycaemia by inhibiting glucagon secretion from pancreatic alpha cells, delaying gastric emptying and mediating induction of satiety<sup><a href="#ref-1">1</a>–<a href="#ref-4">4</a></sup>. Thus, GLP-1 maintains metabolic homeostasis during the postprandial period via multiple actions. For over a decade now, GLP-1 receptor agonists, which have a much longer half-life than endogenous GLP-1, have been an effective treatment option for type 2 diabetes (T2D)<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Interestingly, studies over more recent years have also identified that GLP-1 has beneficial physiological effects on a variety of tissues such as the cardiovascular and neurological systems and this has high clinical relevance given the multiple and common post-diagnosis complications associated with T2D<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-5">5</a>,<a href="#ref-7">7</a>–<a href="#ref-10">10</a></sup>. GLP-1 mediates its effects by binding to its receptor, the GLP-1 receptor (GLP-1R), which is a G protein–coupled receptor that is abundantly present in the pancreatic beta cells, gut, and the central nervous system (CNS) and moderately in the lung, heart, kidney, blood vessels, pancreatic alpha cells, and peripheral nervous system<sup><a href="#ref-2">2</a>,<a href="#ref-4">4</a>,<a href="#ref-7">7</a></sup>. However, studies have reported that GLP-1 exerts its effects on certain extrapancreatic tissues despite the absence of GLP-1R, which implies that this hormone may also act via currently unidentified receptors or mechanisms<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a></sup>. Therefore, given the continual emerging evidence, it has become accepted that GLP-1 has systemic physiological effects and that the actions of this hormone are not limited to mediating the incretin effect, although this is still widely accepted to be GLP-1’s most important and clinically relevant role to date<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a>,<a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. Given these observations, GLP-1–based therapies may also provide new strategies for diseases that can arise independently of T2D in tissues susceptible to GLP-1 action<sup><a href="#ref-7">7</a>,<a href="#ref-11">11</a>,<a href="#ref-13">13</a></sup>. This review aims to summarise the well-established and speculative physiological roles of GLP-1 and highlight what studies have found over recent years in different tissues with regard to the physiological responses induced by endogenous GLP-1 and GLP-1R agonists (used for therapeutic purposes) and discuss the future implications and clinical relevance of these findings.</p><div class=section><a name=d20143e240 class=n-a></a><h3 class=section-title>GLP-1 and its mimetics: physiological roles, therapeutic uses and recent developments</h3><p class="" id=d20143e245>Given the prevalence and incidence of T2D and the disease-associated post-diagnosis complications such as cardiovascular disease (CVD), and the observation that GLP-1 activity is retained in T2D whereas gastric inhibitory polypeptide (GIP) activity is greatly reduced, research was conducted to develop a new therapeutic strategy for T2D treatment using GLP-1–based therapies<sup><a href="#ref-8">8</a>–<a href="#ref-10">10</a>,<a href="#ref-14">14</a></sup>. Initially, success was limited, as endogenous GLP-1 and many of its early analogues have very short half-lives due to rapid inactivation by dipeptidyl peptidase 4 (DPP-4) in the circulation, requiring continuous treatment to maintain therapeutic levels, which was not practical<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a>,<a href="#ref-15">15</a></sup>. However, GLP-1 analogues were developed that had much greater half-life than endogenous GLP-1 whilst retaining the bioactivity<sup><a href="#ref-12">12</a>,<a href="#ref-16">16</a></sup>. GLP-1R agonists used in T2D treatment are either derivatives of native GLP-1 (liraglutide, albiglutide, semaglutide and dulaglutide), which have been modified to be resistant to DPP-4 inactivation, or derivatives of exendin-4 (exenatide, lixisenatide and exenatide-LR)<sup><a href="#ref-4">4</a>,<a href="#ref-17">17</a></sup>. Exendin-4, which shares 53% homology with human GLP-1, was originally isolated from the saliva of the Gila monster lizard and is resistant to the action of DPP-4<sup><a href="#ref-4">4</a></sup>. Key pharmacological and clinical features of clinically available GLP-1R agonists are presented in <a href="#T1">Table 1</a>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Current glucagon-like peptide 1 receptor (GLP-1R) agonists used in type 2 diabetes therapy.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d20143e301 class=n-a></a><thead><a name=d20143e303 class=n-a></a><tr><a name=d20143e305 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d20143e307 class=n-a></a>GLP-1R agonist generic<br class=br>name (trade name)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d20143e312 class=n-a></a>Dosing</th><th align=left colspan=1 rowspan=1 valign=top><a name=d20143e315 class=n-a></a>Half-life</th><th align=left colspan=1 rowspan=1 valign=top><a name=d20143e318 class=n-a></a>Administration<br class=br>required<br class=br>before meals?</th></tr></thead><tbody><a name=d20143e327 class=n-a></a><tr><a name=d20143e329 class=n-a></a><td align=left colspan=4 rowspan=1 valign=top><a name=d20143e331 class=n-a></a>Short-acting</td></tr><tr><a name=d20143e335 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e337 class=n-a></a>Exenatide (Byetta)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e340 class=n-a></a>Twice daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e343 class=n-a></a>2.4hours</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e346 class=n-a></a>Yes</td></tr><tr><a name=d20143e350 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e352 class=n-a></a>Lixisenatide (Lyxumia)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e355 class=n-a></a>Once daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e358 class=n-a></a>4hours</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e361 class=n-a></a>Yes</td></tr><tr><a name=d20143e365 class=n-a></a><td align=left colspan=4 rowspan=1 valign=top><a name=d20143e367 class=n-a></a>Intermediate-acting</td></tr><tr><a name=d20143e371 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e373 class=n-a></a>Liraglutide (Victoza)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e376 class=n-a></a>Once daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e379 class=n-a></a>12hours</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e382 class=n-a></a>No</td></tr><tr><a name=d20143e387 class=n-a></a><td align=left colspan=4 rowspan=1 valign=top><a name=d20143e389 class=n-a></a>Long-acting</td></tr><tr><a name=d20143e393 class=n-a></a><td align=left colspan=4 rowspan=1 valign=top><a name=d20143e395 class=n-a></a>Exenatide-</td></tr><tr><a name=d20143e399 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e401 class=n-a></a>LAR (Bydureon)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e404 class=n-a></a>Once weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e407 class=n-a></a>96hours</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e410 class=n-a></a>No</td></tr><tr><a name=d20143e414 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e416 class=n-a></a>Albiglutide (Tanzeum)<sup><a href="#FN2">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e422 class=n-a></a>Once weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e425 class=n-a></a>6–8 days</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e428 class=n-a></a>No</td></tr><tr><a name=d20143e432 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e434 class=n-a></a>Dulaglutide (Trulicity)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e437 class=n-a></a>Once weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e440 class=n-a></a>90hours</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e443 class=n-a></a>No</td></tr><tr><a name=d20143e447 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e449 class=n-a></a>Semaglutide (Ozempic)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e452 class=n-a></a>Once weekly</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e455 class=n-a></a>165–184hours</td><td align=left colspan=1 rowspan=1 valign=top><a name=d20143e458 class=n-a></a>No</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=FN1 class=n-a></a><p id=d20143e468> Information in this table is taken from <a href="#ref-4">4</a>, <a href="#ref-16">16</a>, <a href="#ref-17">17</a>.</p></div><div class=footnote><a name=FN2 class=n-a></a><p id=d20143e482> <sup>a</sup> This product was globally withdrawn in July 2018 for commercial reasons.</p></div></div></div><p class="" id=d20143e490>These agonists were found to effectively reduce hyperglycaemia in subjects with diabetes by prolonging the incretin effect and have proven to be a welcome addition to the therapeutic armamentarium in patients where insulin therapy was deemed as the next step after the failure of oral hypoglycaemic agents. GLP-1R agonist therapies have low rates of hypoglycaemia and are also associated with weight loss and not weight gain (with current dosages used in therapies), which is an undesirable side effect of some other glucose-lowering therapies<sup><a href="#ref-4">4</a>,<a href="#ref-6">6</a></sup>. The availability of various GLP-1R agonists with differing pharmacokinetic profiles enables individualised treatment options for T2D management, which has clinical relevance given patients’ differing routines, glycaemic control and diets<sup><a href="#ref-4">4</a></sup>. Furthermore, T2D is a highly multifactorial disease and pathology arises in multiple organs<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-14">14</a></sup>. Many of these organs express GLP-1R, which gives GLP-1 analogue therapies the potential to alleviate the diabetic phenotype systemically and the potential to provide new treatments for other diseases such as dementia and CVD in non-diabetic individuals<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a></sup>.</p><p class="" id=d20143e521>In the 1960s, it was shown that orally administered glucose induces a much larger insulin response than that induced by intravenously administered glucose, despite the similar resulting plasma glucose levels: the incretin effect<sup><a href="#ref-18">18</a></sup>. Subsequently, it was identified that two hormones (GIP and GLP-1) released by the gastrointestinal tract (GIT) mediate the incretin effect<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a>,<a href="#ref-19">19</a></sup>. In response to postprandial nutrient loads, enteroendocrine L cells from the intestine secrete GLP-1<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. It has been established that there is a direct correlation between the levels of nutrients exposed to L cells and the levels of GLP-1 in circulation<sup><a href="#ref-20">20</a></sup>. Initially, GLP-1 secretion by L cells was postulated to be dependent on postprandial glucose loads<sup><a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. However, ingestion of mixed nutrients (carbohydrates, fats and proteins) was shown to result in greater GLP-1 secretion in comparison with just glucose ingestion<sup><a href="#ref-21">21</a></sup>. It has also been demonstrated that fats and proteins, like glucose, can independently induce GLP-1 secretion<sup><a href="#ref-20">20</a></sup>. The levels of GLP-1 in fasting plasma are about 5 to 15 pM, which increases to 40 to 60 pM during the postprandial period<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. L cells initiate the GLP-1 response within 15 minutes after food ingestion, and GLP-1 levels peak in the circulation after about 30 minutes<sup><a href="#ref-20">20</a>,<a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. It is still unclear how the GLP-1 response is generated so rapidly but it has been suggested that the vagal nerve and L cells in the upper jejunum part of the small intestine may be involved<sup><a href="#ref-1">1</a></sup>. However, the response is generated after the ‘cephalic phase’ of insulin secretion, implying that neuronal signals that promote insulin release do not influence GLP-1 release<sup><a href="#ref-1">1</a>,<a href="#ref-23">23</a></sup>. Rodent studies have demonstrated that, upon GIP stimulation, the nervous system promotes GLP-1 secretion from L cells, which express the receptors involved in neuronal signalling<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>. However, in chloralose-anaesthetised pigs, electrical stimulation of the vagal trunks at the level of the diaphragm had no effect on GLP-1 secretion, and human cephalic phase studies and studies in vagotomised humans found similar results<sup><a href="#ref-28">28</a>–<a href="#ref-30">30</a></sup>. <a href="#f1">Figure 1</a> summarises the processes in L cells that are known to lead to or that may lead to GLP-1 secretion.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22653/19500564-ba8a-4314-977a-e808ae585949_figure1.gif"><img alt="19500564-ba8a-4314-977a-e808ae585949_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22653/19500564-ba8a-4314-977a-e808ae585949_figure1.gif"></a><div class=caption><h3>Figure 1. Summary of L-cell processes that are known to lead to or that may lead to glucagon-like peptide 1 (GLP-1) secretion into the circulation.</h3><p id=d20143e622>Sodium entry into the L cell promotes calcium influx by inducing depolarisation, and glucose also induces calcium influx by raising ATP levels as a result of its catabolism. The binding of fatty acids to specific receptors also raises intracellular calcium levels. The now-elevated calcium levels promote exocytosis of GLP-1–containing vesicles, releasing GLP-1 into the circulation. Proteins also promote GLP-1 release, but it is not currently mechanistically understood how. L cells have been shown to express receptors for metabolic hormones, including insulin, leptin and gastric inhibitory polypeptide (GIP). The degree to which leptin and insulin stimulate overall GLP-1 secretion is still unclear, but GIP-mediated GLP-1 release has been shown to occur in rodents via acetylcholine release by the enteric nervous system. Supraphysiological concentrations of GIP potentially activate GIP receptors on L cells, potentially enhancing GLP-1 secretion. This figure and information in its legend are adapted from<sup><a href="#ref-26">26</a>,<a href="#ref-37">37</a>–<a href="#ref-41">41</a></sup>.</p></div></div><p class="" id=d20143e639>Studies have revealed that the role of GLP-1 release from L cells is not limited to initiating the desired physiological response to ingested glucose but also proteins and lipids (for example, reducing triglyceride excursions), giving GLP-1 a more diverse role in maintaining metabolic homeostasis during the postprandial period<sup><a href="#ref-2">2</a>,<a href="#ref-20">20</a>,<a href="#ref-21">21</a></sup>. Additionally, understanding the neuronal regulation of GLP-1 release in humans is unclear, as is how other hormones involved in metabolic homeostasis regulate L-cell GLP-1 secretion<sup><a href="#ref-26">26</a>,<a href="#ref-27">27</a></sup>.</p><p class="" id=d20143e659>GLP-1 has a very short half-life (1–2 minutes) in the circulation<sup><a href="#ref-1">1</a></sup> because of its rapid inactivation by proteolytic actions of DPP-4<sup><a href="#ref-1">1</a>,<a href="#ref-7">7</a></sup>. Consequently, it has been become generally accepted that about 85% of GLP-1 exists in the inactive form in circulation<sup><a href="#ref-23">23</a></sup>. Since the majority of GLP-1 is inactivated rapidly after secretion, its response is highly inefficient with regard to ATP expenditure (GLP-1 synthesis requires ATP)<sup><a href="#ref-2">2</a>,<a href="#ref-23">23</a></sup>. It has become generally accepted that endogenous GLP-1 activates sensory afferents of the enteric nervous system, which helps to promote the desired postprandial response, in addition to mediating the incretin effect via the endocrine route to islet beta cells<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. Although it is still unclear why the GLP-1 response is so wasteful from a bioenergetics perspective, recent studies have suggested that the inactive GLP-1 has actions on the liver, vasculature and heart which are comparable to those of insulin<sup><a href="#ref-33">33</a></sup>. However, the notion that GLP-1 has any action on the liver is an area of controversy, given the absence of GLP-1R in hepatocytes<sup><a href="#ref-2">2</a></sup>. Therefore, it is possible that the ‘inactive forms’ are not actually inactive and act on currently unidentified signalling pathways and this seems likely to be the case as it is very unlikely that evolution has developed such an ATP-wasteful response. However, GLP-1R agonists (such as liraglutide and exenatide) that are used in T2D therapy are all synthetically developed. In contrast to endogenous GLP-1, they have a half-life of several hours or more as they are resistant to DPP-4 inactivation<sup><a href="#ref-4">4</a>,<a href="#ref-34">34</a></sup>. This results in prolonged pancreatic beta-cell GLP-1R activation that in turn prolongs the incretin effect, resulting in a reduction of hyperglycaemia in most patients<sup><a href="#ref-4">4</a>,<a href="#ref-35">35</a></sup>.</p><p class="" id=d20143e720>The incretin hormones play a crucial role in maintaining metabolic homeostasis since about 60 to 70% of the total postprandial insulin released into circulation is due to the action of these hormones<sup><a href="#ref-2">2</a>,<a href="#ref-36">36</a></sup>. GIP and GLP-1 account for about 60% and 40% of the incretin effect, respectively<sup><a href="#ref-2">2</a></sup>. The action of GLP-1 is dependent on blood glucose levels since it can only potentiate glucose-stimulated insulin secretion from islet beta cells<sup><a href="#ref-7">7</a></sup>. Furthermore, GLP-1 suppresses glucagon secretion from islet alpha cells, but only when glucose levels are above fasting, which assists in the ability of postprandial insulin to mediate anabolism of ingested nutrients<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-7">7</a></sup>. Given the importance of the correct balance of insulin and glucagon activity being maintained to mediate desired net systemic anabolic or catabolic metabolic effects in response to nutrient supply and demand, GLP-1 activity plays a critical role in maintaining metabolic homeostasis during the postprandial period via insulinotropic and glucagonostatic effects<sup><a href="#ref-2">2</a>,<a href="#ref-4">4</a></sup>. Activation of GLP-1R results in a rapid (seconds to minutes) potentiation of insulin secretion from islet beta cells which is achieved via rapid cAMP production, which results in the activation of protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac), and these two effectors modify several targets in the secretory machinery, resulting in enhanced insulin secretion<sup><a href="#ref-2">2</a>,<a href="#ref-12">12</a></sup>. Additionally, GLP-1R activation results in transcription of genes involved in proliferation, neogenesis and apoptotic resistance in islet beta cells, expanding GLP-1’s role from potentiating insulin secretion from islet beta cells to promoting their survival via translocation of pancreatic duodenal homeobox 1 (PDX-1) transcription factor to the nucleus<sup><a href="#ref-2">2</a>,<a href="#ref-12">12</a>,<a href="#ref-42">42</a></sup>. Chronic liraglutide treatment in diabetic mice was shown to prevent loss of beta-cell mass, by increasing the proliferation of beta cells and decreasing beta-cell apoptosis, after alloxan injection<sup><a href="#ref-35">35</a></sup>. Inhibition of beta-cell apoptosis in isolated human pancreatic beta cells was also reported after liraglutide administration, and the beta-cell proliferation rate was increased up to threefold after incubation for 24 hours<sup><a href="#ref-43">43</a></sup>. In both animal and human studies, GLP-1/exendin-4 has also been shown to increase the beta-cell mass<sup><a href="#ref-44">44</a></sup>. Endogenous GLP-1 not only protects against apoptosis but also induces proliferation of rat primary islet cells and beta-cell lines<sup><a href="#ref-12">12</a>,<a href="#ref-45">45</a></sup>. GLP-1R activation has also been proposed to reduce lipotoxicity, glucotoxicity, Ca<sup>2+</sup> depletion, excess nitric oxide, cytokine-induced endoplasmic reticulum (ER) stress and oxidative stress in both primary beta cells and cell lines via multiple downstream signalling pathways<sup><a href="#ref-46">46</a>–<a href="#ref-50">50</a></sup>. One study found that GLP-1R signalling alters the intracellular response from the translational repression to the translational recovery phase in a PKA-dependent manner<sup><a href="#ref-46">46</a></sup>. GLP-1 has recently been shown to regulate autophagy in beta cells<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>. Exendin-4 treatment was shown to facilitate autophagy in rat INS-1E cells and isolated human islets under chronic exposure to excess nutrients by preventing autophagosomal-lysosomal fusion impairment. Its treatment was also reported to increase lysosomal function, which improved autophagosome clearance and thereby reduced islet beta-cell injury in a rat model of tacrolimus-induced diabetes<sup><a href="#ref-53">53</a></sup>. Additionally, exendin-4 treatment <i>in vivo</i> has been shown to decrease tacrolimus-induced oxidative stress, hyperglycemia, and apoptosis [43]. Interestingly, recent studies have found that chronic GLP-1R activation results in metabolic reprogramming associated with upregulation of glycolytic enzymes and increased ATP production<sup><a href="#ref-54">54</a></sup>. It has been postulated that an enhancement in metabolism by GLP-1 treatment likely decreases ER stress by increasing intracellular Ca<sup>2+</sup> and mitochondrial ATP levels, which then are used in the maintenance of ER homeostasis<sup><a href="#ref-12">12</a></sup>. Interestingly, chronic GLP-1R activation also results in the activation of distinct signalling pathways; for instance, GLP-1R agonists have been reported to promote the secretion of insulin-like growth factor 2 and induce expression of its receptor, which is thought to contribute to the pro-survival abilities of GLP-1 in islet beta cells<sup><a href="#ref-12">12</a>,<a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>. Given that ER stress, impaired autophagy and proliferation, and increased apoptosis are all thought to contribute to islet beta-cell dysfunction in T2D, and the findings that GLP-1R activation can alleviate all of these, suggests GLP-1 and its analogues do more than just augmenting insulin secretion<sup><a href="#ref-12">12</a></sup>. However, currently, there are no data from recent long-term clinical studies to suggest that GLP-1–based therapies exert protective effects on islet beta cells, and it is unclear whether the maximum insulin enhancement is achieved with present dosages used clinically, which are currently limited by side effects<sup><a href="#ref-10">10</a>,<a href="#ref-57">57</a>–<a href="#ref-60">60</a></sup>. <a href="#f2">Figure 2</a> summarises the processes in islet beta cells that are influenced by postprandial glucose loads and GLP-1 action.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22653/19500564-ba8a-4314-977a-e808ae585949_figure2.gif"><img alt="19500564-ba8a-4314-977a-e808ae585949_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22653/19500564-ba8a-4314-977a-e808ae585949_figure2.gif"></a><div class=caption><h3>Figure 2. Summary of islet beta-cell processes that are influenced by postprandial glucose loads and glucagon-like peptide 1 (GLP-1) action.</h3><p id=d20143e871>When the plasma glucose rises, glucokinase initiates glucose catabolism, resulting in an increase in the cell’s ATP levels, which results in closure of ATP-sensitive potassium channels, causing membrane depolarisation and calcium influx. The resulting calcium influx triggers insulin secretion by promoting movement of insulin vesicles to the cell membrane. The binding of GLP-1 to GLP-1R enhances glucose-stimulated insulin secretion by initiating cAMP production via adenylyl cyclase activity that in turn activates protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). Activated PKA and Epac augment extracellular calcium influx induced by glucose catabolism via further promoting closure of potassium channels, and Epac also raises the intracellular calcium levels directly via promoting calcium release from the endoplasmic reticulum. Evidence suggests that PKA increases the permeability of calcium channels, which further enhances the influx of extracellular calcium. The elevated intracellular calcium levels further enhance exocytosis of insulin vesicles. The activation of GLP-1R also induces activation of PDX-1 transcription factor and its translocation to the nucleus, which results in the transcription of the preproinsulin, GLUT2 and glucokinase genes for further insulin production, glucose uptake and glucose catabolism, respectively. PDX-1 activation also induces the transcription of genes involved in apoptotic resistance, neogenesis and proliferation, giving GLP-1 a role in promoting beta-cell survival during the postprandial period in addition to enhancing insulin secretion. Studies have found that GLP-1R activation enhances autophagy and metabolic profiles and reduces ER stress via PKA-dependent mechanisms. This figure and information in its legend are adapted from<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-46">46</a>–<a href="#ref-52">52</a>,<a href="#ref-56">56</a></sup>.</p></div></div><p class="" id=d20143e894>The regulation of alpha cells by GLP-1 remains an area of controversy<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a>,<a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. However, it is firmly established that the ability of GLP-1 to inhibit glucagon secretion is not dependent on its insulinotropic effects, given that GLP-1 is able to lower fasting plasma glucose levels in people with type 1 diabetes<sup><a href="#ref-7">7</a>,<a href="#ref-63">63</a></sup>. Despite the low and controversial GLP-1R expression in islet alpha cells, recent studies have provided evidence that GLP-1R agonists mediate direct effects on alpha cells via the presence of GLP-1R<sup><a href="#ref-7">7</a>,<a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. Islet alpha-cell GLP-1R knockout mice failed to inhibit glucagon secretion at high glucose levels; interestingly, these mice had impaired glucagon secretion during low glucose conditions<sup><a href="#ref-62">62</a></sup>. Another recent study found that GLP-1 action on human pancreatic islet alpha cells was not dependent on paracrine signalling since preventing insulin and somatostatin signalling had no effect on the inhibition of glucagon secretion<sup><a href="#ref-61">61</a></sup>. Until recently, there was a strong consensus in the literature that GLP-1 acts on alpha cells through an unidentified receptor or through paracrine mechanisms (or both) via insulin and somatostatin release from islet beta and delta cells, respectively<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a></sup>. Hyperglycaemia in T2D is now accepted to be induced by both hyperglucagonemia and hypoinsulinemia, and up to 50% of the excess plasma glucose levels in patients has been postulated to arise from inappropriate glucagon secretion<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. Given that T2D is now considered to be a bihormonal disorder, how GLP-1R agonists influence glucagon secretion is of high clinical relevance<sup><a href="#ref-7">7</a>,<a href="#ref-66">66</a></sup>.</p><p class="" id=d20143e958>Studies have revealed that GLP-1 has multiple extrapancreatic targets and effects, which not only assists with inducing the desired physiological response during the postprandial period but also has beneficial effects on alleviating pathology associated with certain tissues and organs systemically, which arises because of T2D manifestation or independently of T2D<sup><a href="#ref-2">2</a>,<a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-12">12</a></sup>. These findings are of clinical importance since there is demand for new therapeutic strategies that both reduce the prevalence and incidence of T2D post-diagnosis complications and provide better prognosis than current treatments for diseases such as dementia<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a>–<a href="#ref-9">9</a>,<a href="#ref-12">12</a></sup>. Indeed, recent studies have found that certain GLP-1 analogue therapies confer cardiovascular benefits to people with diabetes, which has high clinical importance given the prevalence of the cardiovascular comorbidity of diabetes<sup><a href="#ref-10">10</a></sup>. Owing to the weight loss achieved as a result of the ability of this drug to mediate satiety, liraglutide was also recently approved for the treatment of obesity in individuals without diabetes<sup><a href="#ref-67">67</a></sup>. It was initially postulated that the effect of GLP-1 on appetite could be due to its negative regulation of gut motility; however, evidence that GLP-1 has direct effects on specific neurons in the hypothalamus has emerged<sup><a href="#ref-24">24</a></sup>. GLP-1 is expressed in neurons of the brainstem and GLP-1R is present in the hypothalamic areas that control energy homeostasis and food intake, including the arcuate nucleus, paraventricular nucleus, and dorsomedial nucleus<sup><a href="#ref-1">1</a>,<a href="#ref-68">68</a></sup>. Intracerebroventricular injection of GLP-1 inhibits food intake in rats and this activity is blocked by exendin<sub>9–39</sub>, demonstrating that GLP-1 has direct effects on neurons<sup><a href="#ref-69">69</a>,<a href="#ref-70">70</a></sup>. Studies have shown that intracerebroventricular administration of GLP-1 in humans induces satiety even in the absence of food in the GIT and when gastric emptying has been inhibited; thus, GLP-1 induces satiety via its direct effects on neurons in the caudal brainstem<sup><a href="#ref-1">1</a>,<a href="#ref-24">24</a>,<a href="#ref-68">68</a></sup>. The mechanism by which peripherally administered GLP-1 induces satiety has yet to be elucidated, but it likely involves signals being generated by GLP-1 binding to GLP-1R on neurons in the GIT, hepatoportal bed and CNS<sup><a href="#ref-1">1</a>,<a href="#ref-71">71</a></sup>. The differences in weight loss reported for the various GLP-1 analogues currently used to treat T2D are likely related to their penetration of the CNS, allowing central GLP-1R binding<sup><a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. Additionally, some studies have found evidence that GLP-1–based therapies alleviate pathology associated with other diseases such as dementia in non-diabetic individuals, although there is controversy about the potential for these therapies in dementia treatment based on different findings, especially in human studies<sup><a href="#ref-12">12</a>,<a href="#ref-74">74</a></sup>. Non-alcoholic fatty liver disease (NAFLD) and subsequent non-alcoholic steatohepatitis (NASH) are highly prevalent among individuals with T2D or obesity (or both) because of the excessive hepatic fat deposition associated with these diseases<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. Studies have found that GLP-1R agonist treatments reduce liver pathology not only by promoting weight loss and improving glycaemic control but also by reducing alanine aminotransferase (ALT) levels, which was linked to the degree of weight loss induced<sup><a href="#ref-75">75</a></sup>. The ability of GLP-1R agonists to reduce weight and lower ALT levels suggests a role for these compounds in treating NAFLD/NASH and reducing liver damage. A recent study found that semaglutide treatment significantly reduced ALT levels in NAFLD at-risk patients, and histological data are awaited from an ongoing phase 2 trial of semaglutide in biopsy-proven NASH<sup><a href="#ref-76">76</a></sup>. <a href="#f3">Figure 3</a> summarises the findings from studies on the extrapancreatic effects of GLP-1-based therapies and the clinical implications of these findings.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/22653/19500564-ba8a-4314-977a-e808ae585949_figure3.gif"><img alt="19500564-ba8a-4314-977a-e808ae585949_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/22653/19500564-ba8a-4314-977a-e808ae585949_figure3.gif"></a><div class=caption><h3>Figure 3. Summary of the reported extrapancreatic effects of glucagon-like peptide 1 (GLP-1)-based therapies (A–C) and the clinical implications of these findings (D).</h3><p id=d20143e1077>In frame C, organs that are underlined indicate that GLP-1 receptor (GLP-1R) expression is controversial/unconfirmed, and it is not clear whether or how GLP-1 is able to mediate any direct physiological effects on them. ANP, atrial natriuretic peptide; CVS, cardiovascular system; eNOS, endothelial nitric oxide synthase; EPAC, exchange protein directly activated by cAMP; ERK1/2, extracellular signal-related kinase 1/2; MAPK, mitogen-activated protein kinase; NOD, non-obese diabetic; PI3K, phosphoinositide-3-kinase; PKA, protein kinase A; ROS, reactive oxidative species; T1D, type 1 diabetes; T2D, type 2 diabetes; T2DM, type 2 diabetes mellitus; VCAM, vascular cell adhesion molecule-1; VEGF, vascular endothelial growth factor. This figure and information in its legend are adapted from <a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-7">7</a>,<a href="#ref-12">12</a>,<a href="#ref-77">77</a>,<a href="#ref-78">78</a>,<a href="#ref-79">79</a>–<a href="#ref-98">98</a>.</p></div></div><p class="" id=d20143e1109>A recent longitudinal study found that GLP-1–based agonist action may not only be an effective treatment for T2D but also prevent or delay disease manifestation in at-risk individuals: Liraglutide treatment reduced the risk of T2D manifestation in obese individuals and individuals who had a body mass index of more than 27 and had hypertension or dyslipidaemia; after 160 weeks, the liraglutide-treated group (n = 1472) had a smaller percentage of the population with diagnosed T2D (2% versus 6%) than the placebo-treated control group (n = 738)<sup><a href="#ref-99">99</a></sup>. Additionally, time to T2D onset during the 160-week study was found to be 2.7 times longer in the liraglutide-treated group than the placebo control group. Interestingly, recent studies have also demonstrated that the therapeutic potential of GLP-1 action in the treatment of diseases such as T2D and dementia can likely be enhanced by co-activation of other receptors involved in maintaining metabolic homeostasis. The dual GLP-1R and GIP receptor (GIPR) agonist treatment induced better glycaemic control and body weight reduction in diet-induced obesity (DIO) mice compared with liraglutide (GLP-1R agonist)-only-treated controls<sup><a href="#ref-100">100</a></sup>. Co-agonism of GLP-1R and glucagon receptor (GR) was also shown to reduce body weight synergistically in rodent obesity models<sup><a href="#ref-101">101</a></sup>. These co-agonists have also improved glycaemic control in monkeys and humans<sup><a href="#ref-100">100</a></sup>. In a recent study, tirzepatide, a novel GLP-1R and GIPR co-agonist, was found to induce greater glucose control and weight loss in human patients with T2D than duglatide (a GLP-1R–only agonist)<sup><a href="#ref-102">102</a></sup>. Recently, a triple agonist for GLP-1R, GR and GIPR was developed and tested on DIO mice, and it was found that the tri-agonist lowered body weight to a greater extent than GLP-1R/GIPR co-agonist treatment<sup><a href="#ref-103">103</a></sup>. The co-agonist and the tri-agonist were equally effective at reducing blood glucose levels and improving glucose tolerance without the induction of hypoglycaemia and this demonstrates that chronic GR agonism does not counteract the anti-hyperglycemic effects of GLP-1R and GIPR activity. Surprisingly, tri-agonist treatment lowered plasma insulin levels to a greater extent than the GLP-1R/GIPR co-agonist, indicating improved insulin sensitivity. Interestingly, no difference in food intake was observed between wild-type mice treated with the dual incretin GLP-1R/GIPR co-agonist and those treated with the tri-agonist despite the difference in weight loss and this was found to be due to significantly enhanced ATP expenditure in tri-agonist–treated DIO mice. The capacity of the tri-agonist to prevent the development of spontaneous diabetes compared with the dual incretin GLP-1R/GIPR co-agonist was also tested in mouse models of T2D. The tri-agonist treatment prevented the excessive weight gain in vehicle-treated mice to a greater degree than the GLP-1R/GIPR co-agonist and this difference was not due to cumulative food intake. The tri-agonist also protected these mice from fasting hyperglycaemia and to a better degree than the GLP-1R/GIPR co-agonist. Interestingly, the tri-agonist also significantly reduced alpha-cell infiltration into the core of pancreatic islets, helping to preserve the islet architecture observed in healthy pancreatic islets. Glycaemic improvements were maintained in Zucker diabetic fatty rats 3 weeks after treatment cessation although they had gained body weight and were comparable in mass to vehicle-treated controls, demonstrating that the tri-agonist delays T2D progression in rodent models of spontaneous diabetes. Interestingly, this study also demonstrated that the effects of the tri-agonist are dependent on an excess of nutrient storage as weight and food intake were not altered in lean mice even after chronic treatment with the tri-agonist. A recent study also found that tri-agonist treatment was able to ameliorate diet-induced steatohepatitis in mice<sup><a href="#ref-77">77</a></sup>. However, the clinical importance of the co- and tri-agonists has yet to be established since the majority of the studies using these agonists were carried using rodent models. Some GLP1R/GIPR co-agonists are in clinical development for T2DM treatment.</p></div><div class=section><a name=d20143e1142 class=n-a></a><h3 class=section-title>Summary</h3><p class="" id=d20143e1147>In summary, abundant evidence has emerged over recent years to demonstrate that GLP-1 has multiple pancreatic effects and extrapancreatic targets and actions throughout the body, which likely play a significant role in maintaining metabolic homeostasis during healthy conditions and therefore to label GLP-1 as just an ‘incretin hormone’ is now outdated<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-7">7</a>,<a href="#ref-12">12</a></sup>. Thus, GLP-1 has a much more complex and diverse physiological role than previously thought. Despite all the research that has been conducted on GLP-1 and its actions, the mechanisms that regulate the secretion of this hormone are still not fully understood, nor are the mechanisms by which it exerts its actions. It is unclear whether GLP-1 is able to mediate its effects by an unidentified receptor, and there is controversy as to whether the inactive forms are able to induce physiological effects<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a>,<a href="#ref-12">12</a></sup>. Native GLP-1 has no use therapeutically, but the advent of GLP-1R agonists that have much longer half-lives has enabled GLP-1–based actions for therapeutic uses as a viable option<sup><a href="#ref-5">5</a>–<a href="#ref-7">7</a></sup>). Initially, GLP-1R agonists were thought to be limited to T2D treatment, but it has become clear that these drugs have the potential to treat other diseases such as obesity, CVD, dementia and NAFLD<sup><a href="#ref-2">2</a>,<a href="#ref-7">7</a>,<a href="#ref-12">12</a>,<a href="#ref-77">77</a></sup>,<a href="#ref-103">103</a>. Better understanding the mechanisms and signalling pathways by which acute and chronic GLP-1R activation both alleviates disease phenotypes and induces desirable physiological responses during healthy conditions will likely lead to the development of new therapeutic GLP-1 action–based therapies, which improve prognosis to a greater extent than current therapies. Importantly, the observations that GLP-1–based therapies delay/prevent the manifestation of T2D<sup><a href="#ref-99">99</a></sup> may enable expansion of the role of GLP-1 mimetics from treating diseases to delaying or preventing diseases manifesting in tissues susceptible to GLP-1–based action. Additionally, given the observations from co- and tri-agonist studies, future research will need to investigate what the long-term effects of synergistic activation of other receptors will be<sup><a href="#ref-78">78</a></sup>,<a href="#ref-100">100</a>,<a href="#ref-101">101</a>,<a href="#ref-103">103</a>. Finally, over recent years, allosteric agonists that act on sites distinct from those of GLP-1 and its mimetics have been developed for the GLP-1R<sup><a href="#ref-23">23</a></sup>. Research is ongoing to determine whether these agonists can modulate GLP-1R downstream effectors to better alleviate pathology than current GLP-1R agonists used in the therapy. One advantage of these allosteric agonists is that, in contrast to current therapies which require injection, they can be administered orally. Ongoing and future research into the modulation of GLP-1 action will likely lead to the development of new therapeutic strategies for an array of diseases.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d20143e1222>Abbreviations</h2><p class="" id=d20143e1225>ALT, alanine aminotransferase; CNS, central nervous system; CVD, cardiovascular disease; DIO, diet-induced obesity; DPP-4, dipeptidyl peptidase 4; ER, endoplasmic reticulum; GIP, gastric inhibitory polypeptide; GIPR, gastric inhibitory polypeptide receptor; GIT, gastrointestinal tract; GLP-1, glucagon-like peptide 1; GLP-1R; glucagon-like peptide 1 receptor; GR, glucagon receptor; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PKA, protein kinase A; T2D, type 2 diabetes</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d20143e1232 class=n-a></a><h2 class=main-title id=d20143e1234>Acknowledgements</h2><p class="" id=d20143e1237>The work in VK’s laboratory was supported by Biotechnology and Biological Sciences Research Council (BBSRC) UK (BB/F017596/1). JR holds a Knowledge Economy Skills Scholarship (KESS) UK PhD studentship. We thank members of the VK laboratory.</p></div><div class=back-section><a name=d20143e1241 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d20759>References</h2><div class="section ref-list"><a name=d20143e1241 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d20143e1248 class=n-a></a>Holst JJ: The physiology of glucagon-like peptide 1. <i>Physiol Rev.</i> 2007; <b>87</b>(4): 1409–39. <a target=xrefwindow id=d20143e1256 href="http://www.ncbi.nlm.nih.gov/pubmed/17928588">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1259 href="https://doi.org/10.1152/physrev.00034.2006">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d20143e1268 class=n-a></a>Reed J, Kanamarlapudi V:GLP-1. In: Choi S, editor. <i>Encyclopedia of Signaling Molecules</i>. Cham: Springer International Publishing; 2018; 2098–106.</span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d20143e1280 class=n-a></a>De Marinis YZ, Salehi A, Ward CE, <i> et al.</i>: GLP-1 inhibits and adrenaline stimulates glucagon release by differential moduladtion of N- and L-type Ca<sup>2+</sup> channel-dependent exocytosis. <i>Cell Metab.</i> 2010; <b>11</b>(6): 543–53. <a target=xrefwindow id=d20143e1294 href="http://www.ncbi.nlm.nih.gov/pubmed/20519125">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1298 href="https://doi.org/10.1016/j.cmet.2010.04.007">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d20143e1307 class=n-a></a>Rajeev SP, Wilding J: GLP-1 as a target for therapeutic intervention. <i>Curr Opin Pharmacol.</i> 2016; <b>31</b>: 44–9. <a target=xrefwindow id=d20143e1315 href="http://www.ncbi.nlm.nih.gov/pubmed/27591964">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1318 href="https://doi.org/10.1016/j.coph.2016.08.005">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d20143e1327 class=n-a></a>Aroda VR: A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. <i>Diabetes Obes Metab.</i> 2018; <b>20(Suppl 1)</b>: 22–33. <a target=xrefwindow id=d20143e1335 href="http://www.ncbi.nlm.nih.gov/pubmed/29364586">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1338 href="https://doi.org/10.1111/dom.13162">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d20143e1348 class=n-a></a>Prasad-Reddy L, Isaacs D: A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. <i>Drugs Context.</i> 2015; <b>4</b>: 212283. <a target=xrefwindow id=d20143e1356 href="http://www.ncbi.nlm.nih.gov/pubmed/26213556">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1359 href="https://doi.org/10.7573/dic.212283">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726741818"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e1368 class=n-a></a>Graaf Cd, Donnelly D, Wootten D, <i> et al.</i>: Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes. <i>Pharmacol Rev.</i> 2016; <b>68</b>(4): 954–1013. <a target=xrefwindow id=d20143e1379 href="http://www.ncbi.nlm.nih.gov/pubmed/27630114">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1382 href="https://doi.org/10.1124/pr.115.011395">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1386 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5050443">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726741818">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d20143e1398 class=n-a></a>Iglay K, Hannachi H, Joseph Howie P, <i> et al.</i>: Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. <i>Curr Med Res Opin.</i> 2016; <b>32</b>(7): 1243–52. <a target=xrefwindow id=d20143e1409 href="http://www.ncbi.nlm.nih.gov/pubmed/26986190">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1412 href="https://doi.org/10.1185/03007995.2016.1168291">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d20143e1421 class=n-a></a>Juster-Switlyk K, Smith AG: Updates in diabetic peripheral neuropathy [version 1; peer review: 3 approved]. <i>F1000Res.</i> 2016; <b>5</b>: pii: F1000 Faculty Rev-738. <a target=xrefwindow id=d20143e1429 href="http://www.ncbi.nlm.nih.gov/pubmed/27158461">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1432 href="https://doi.org/10.12688/f1000research.7898.1">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1435 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4847561">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d20143e1444 class=n-a></a>Reed J, Kanamarlapudi V, Bain S: Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. <i>Cardiovasc Endocrinol Metab.</i> 2018; <b>7</b>(1): 18–23. <a target=xrefwindow id=d20143e1452 href="http://www.ncbi.nlm.nih.gov/pubmed/31646274">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1455 href="https://doi.org/10.1097/XCE.0000000000000147">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1458 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6739887">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d20143e1467 class=n-a></a>Katsurada K, Yada T: Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. <i>J Diabetes Investig.</i> 2016; <b>7</b>(Suppl 1): 64–9. <a target=xrefwindow id=d20143e1475 href="http://www.ncbi.nlm.nih.gov/pubmed/27186358">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1478 href="https://doi.org/10.1111/jdi.12464">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4854507">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734616040"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e1491 class=n-a></a>Rowlands J, Heng J, Newsholme P, <i> et al.</i>: Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. <i>Front Endocrinol (Lausanne).</i> 2018; <b>9</b>: 672. <a target=xrefwindow id=d20143e1502 href="http://www.ncbi.nlm.nih.gov/pubmed/30532733">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1505 href="https://doi.org/10.3389/fendo.2018.00672">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1509 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6266510">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734616040">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d20143e1522 class=n-a></a>Yildirim Simsir I, Soyaltin UE, Cetinkalp S: Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. <i>Diabetes Metab Syndr.</i> 2018; <b>12</b>(3): 469–75. <a target=xrefwindow id=d20143e1530 href="http://www.ncbi.nlm.nih.gov/pubmed/29598932">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1533 href="https://doi.org/10.1016/j.dsx.2018.03.002">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d20143e1542 class=n-a></a>Chawla A, Chawla R, Jaggi S: Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? <i>Indian J Endocrinol Metab.</i> 2016; <b>20</b>(4): 546–51. <a target=xrefwindow id=d20143e1550 href="http://www.ncbi.nlm.nih.gov/pubmed/27366724">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1553 href="https://doi.org/10.4103/2230-210.183480">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1556 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4911847">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d20143e1565 class=n-a></a>Gupta V: Glucagon-like peptide-1 analogues: An overview. <i>Indian J Endocrinol Metab.</i> 2013; <b>17</b>(3): 413–21. <a target=xrefwindow id=d20143e1573 href="http://www.ncbi.nlm.nih.gov/pubmed/23869296">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1576 href="https://doi.org/10.4103/2230-8210.111625">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1579 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3712370">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d20143e1588 class=n-a></a>Hinnen D: Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. <i>Diabetes Spectr.</i> 2017; <b>30</b>(3): 202–10. <a target=xrefwindow id=d20143e1596 href="http://www.ncbi.nlm.nih.gov/pubmed/28848315">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1599 href="https://doi.org/10.2337/ds16-0026">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1602 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5556578">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d20143e1611 class=n-a></a>Goldenberg RM, Steen O: Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. <i>Can J Diabetes.</i> 2019; <b>43</b>(2): 136–45. <a target=xrefwindow id=d20143e1619 href="http://www.ncbi.nlm.nih.gov/pubmed/30195966">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1622 href="https://doi.org/10.1016/j.jcjd.2018.05.008">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d20143e1632 class=n-a></a>Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. <i>J Clin Invest.</i> 1967; <b>46</b>(12): 1954–62. <a target=xrefwindow id=d20143e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/6074000">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1643 href="https://doi.org/10.1172/JCI105685">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1646 href="http://www.ncbi.nlm.nih.gov/pmc/articles/292948">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d20143e1655 class=n-a></a>Shields D, Warren TG, Roth SE, <i> et al.</i>: Cell-free synthesis and processing of multiple precursors to glucagon. <i>Nature.</i> 1981; <b>289</b>(5797): 511–4. <a target=xrefwindow id=d20143e1666 href="http://www.ncbi.nlm.nih.gov/pubmed/6110189">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1669 href="https://doi.org/10.1038/289511a0">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d20143e1678 class=n-a></a>Wang X, Liu H, Chen J, <i> et al.</i>: Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. <i>Int J Endocrinol.</i> 2015; <b>2015: 651757</b><a target=xrefwindow id=d20143e1688 href="http://www.ncbi.nlm.nih.gov/pubmed/26366173">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1691 href="https://doi.org/10.1155/2015/651757">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1694 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4558455">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d20143e1703 class=n-a></a>Ahlkvist L, Vikman J, Pacini G, <i> et al.</i>: Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. <i>Regul Pept.</i> 2012; <b>178</b>(1–3): 29–35. <a target=xrefwindow id=d20143e1714 href="http://www.ncbi.nlm.nih.gov/pubmed/22750278">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1717 href="https://doi.org/10.1016/j.regpep.2012.06.004">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d20143e1726 class=n-a></a>Padidela R, Patterson M, Sharief N, <i> et al.</i>: Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period. <i>Eur J Endocrinol.</i> 2009; <b>160</b>(1): 53–8. <a target=xrefwindow id=d20143e1737 href="http://www.ncbi.nlm.nih.gov/pubmed/18952761">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1740 href="https://doi.org/10.1530/EJE-08-0807">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d20143e1749 class=n-a></a>Thompson A, Kanamarlapudi V: Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. <i>Clin Exp Pharmacol.</i> 2013; <b>03</b>. <a target=xrefwindow id=d20143e1757 href="https://doi.org/10.4172/2161-1459.1000138">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d20143e1767 class=n-a></a>Dailey MJ, Moran TH: Glucagon-like peptide 1 and appetite. <i>Trends Endocrinol Metab.</i> 2013; <b>24</b>(2): 85–91. <a target=xrefwindow id=d20143e1775 href="http://www.ncbi.nlm.nih.gov/pubmed/23332584">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1778 href="https://doi.org/10.1016/j.tem.2012.11.008">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1781 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3594872">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d20143e1790 class=n-a></a>Wang Z, Thurmond DC: Mechanisms of biphasic insulin-granule exocytosis – roles of the cytoskeleton, small GTPases and SNARE proteins. <i>J Cell Sci.</i> 2009; <b>122</b>(Pt 7): 893–903. <a target=xrefwindow id=d20143e1798 href="http://www.ncbi.nlm.nih.gov/pubmed/19295123">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1801 href="https://doi.org/10.1242/jcs.034355">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1804 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2720925">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d20143e1813 class=n-a></a>Anini Y, Hansotia T, Brubaker PL: Muscarinic receptors control postprandial release of glucagon-like peptide-1: <i>in vivo</i> and <i>in vitro</i> studies in rats. <i>Endocrinology.</i> 2002; <b>143</b>(6): 2420–6. <a target=xrefwindow id=d20143e1827 href="http://www.ncbi.nlm.nih.gov/pubmed/12021207">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1831 href="https://doi.org/10.1210/endo.143.6.8840">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d20143e1840 class=n-a></a>Pais R, Gribble FM, Reimann F: Stimulation of incretin secreting cells. <i>Ther Adv Endocrinol Metab.</i> 2016; <b>7</b>(1): 24–42. <a target=xrefwindow id=d20143e1848 href="http://www.ncbi.nlm.nih.gov/pubmed/26885360">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1851 href="https://doi.org/10.1177/2042018815618177">Publisher Full Text </a> | <a target=xrefwindow id=d20143e1854 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4740941">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d20143e1863 class=n-a></a>Hansen L, Lampert S, Mineo H, <i> et al.</i>: Neural regulation of glucagon-like peptide-1 secretion in pigs. <i>Am J Physiol Endocrinol Metab.</i> 2004; <b>287</b>(5): E939–E947. <a target=xrefwindow id=d20143e1874 href="http://www.ncbi.nlm.nih.gov/pubmed/15475512">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1877 href="https://doi.org/10.1152/ajpendo.00197.2004">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d20143e1886 class=n-a></a>Plamboeck A, Veedfald S, Deacon CF, <i> et al.</i>: The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2013; <b>304</b>(12): G1117–G1127. <a target=xrefwindow id=d20143e1897 href="http://www.ncbi.nlm.nih.gov/pubmed/23599045">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1900 href="https://doi.org/10.1152/ajpgi.00035.2013">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d20143e1910 class=n-a></a>Veedfald S, Plamboeck A, Deacon CF, <i> et al.</i>: Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. <i>Am J Physiol Gastrointest Liver Physiol.</i> 2016; <b>310</b>(1): G43–51. <a target=xrefwindow id=d20143e1921 href="http://www.ncbi.nlm.nih.gov/pubmed/26492921">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1924 href="https://doi.org/10.1152/ajpgi.00222.201">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d20143e1933 class=n-a></a>Knauf C, Abot A, Wemelle E, <i> et al.</i>: Targeting the Enteric Nervous System to Treat Metabolic Disorders? “Enterosynes” as Therapeutic Gut Factors. <i>Neuroendocrinology.</i> 2020; <b>110</b>(1–2): 139–46. <a target=xrefwindow id=d20143e1944 href="http://www.ncbi.nlm.nih.gov/pubmed/31280267">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1947 href="https://doi.org/10.1159/000500602">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735970898"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e1956 class=n-a></a>Varin EM, Mulvihill EE, Baggio LL, <i> et al.</i>: Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action. <i>Cell Rep.</i> 2019; <b>27</b>(11): 3371–3384.e3. <a target=xrefwindow id=d20143e1967 href="http://www.ncbi.nlm.nih.gov/pubmed/31189118">PubMed Abstract </a> | <a target=xrefwindow id=d20143e1970 href="https://doi.org/10.1016/j.celrep.2019.05.055">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735970898">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d20143e1982 class=n-a></a>Sharma R, McDonald TS, Eng H, <i> et al.</i>: <i>In vitro</i> metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. <i>Drug Metab Dispos.</i> 2013; <b>41</b>(12): 2148–57. <a target=xrefwindow id=d20143e1996 href="http://www.ncbi.nlm.nih.gov/pubmed/24056839">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2000 href="https://doi.org/10.1124/dmd.113.054254">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d20143e2009 class=n-a></a>Koole C, Pabreja K, Savage EE, <i> et al.</i>: Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. <i>Biochem Soc Trans.</i> 2013; <b>41</b>(1): 172–9. <a target=xrefwindow id=d20143e2020 href="http://www.ncbi.nlm.nih.gov/pubmed/23356279">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2023 href="https://doi.org/10.1042/BST20120236">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d20143e2032 class=n-a></a>Tamura K, Minami K, Kudo M, <i> et al.</i>: Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice. <i>PLoS One.</i> 2015; <b>10</b>(5): e0126003. <a target=xrefwindow id=d20143e2043 href="http://www.ncbi.nlm.nih.gov/pubmed/25938469">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2046 href="https://doi.org/10.1371/journal.pone.0126003">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2050 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4418765">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d20143e2060 class=n-a></a>Salehi M, Aulinger B, D'Alessio DA: Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. <i>Diabetes.</i> 2012; <b>61</b>(11): 2728–33. <a target=xrefwindow id=d20143e2068 href="http://www.ncbi.nlm.nih.gov/pubmed/22733799">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2071 href="https://doi.org/10.2337/db11-1825">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2074 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3478560">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d20143e2083 class=n-a></a>Gribble FM, Williams L, Simpson AK, <i> et al.</i>: A Novel Glucose-Sensing Mechanism Contributing to Glucagon-Like Peptide-1 Secretion From the GLUTag Cell Line. <i>Diabetes.</i> 2003; <b>52</b>(5): 1147–54. <a target=xrefwindow id=d20143e2094 href="http://www.ncbi.nlm.nih.gov/pubmed/12716745">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2097 href="https://doi.org/10.2337/diabetes.52.5.1147">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d20143e2106 class=n-a></a>Lim GE, Brubaker PL: Glucagon-Like Peptide 1 Secretion by the L-Cell: The View From Within. <i>Diabetes.</i> 2006; <b>55</b>(Supplement 2): S70–S77. <a target=xrefwindow id=d20143e2114 href="https://doi.org/10.2337/db06-S020">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d20143e2123 class=n-a></a>Lim GE, Huang GJ, Flora N, <i> et al.</i>: Insulin Regulates Glucagon-Like Peptide-1 Secretion From the Enteroendocrine L Cell. <i>Endocrinology.</i> 2009; <b>150</b>(2): 580–91. <a target=xrefwindow id=d20143e2134 href="http://www.ncbi.nlm.nih.gov/pubmed/18818290">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2137 href="https://doi.org/10.1210/en.2008-0726">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2141 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5393261">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d20143e2150 class=n-a></a>Reimann F, Habib AM, Tolhurst G, <i> et al.</i>: Glucose Sensing in L Cells: a Primary Cell Study. <i>Cell Metab.</i> 2008; <b>8</b>(6): 532–9. <a target=xrefwindow id=d20143e2161 href="http://www.ncbi.nlm.nih.gov/pubmed/19041768">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2164 href="https://doi.org/10.1016/j.cmet.2008.11.002">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2168 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2697331">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d20143e2177 class=n-a></a>Tian L, Jin T: The Incretin Hormone GLP-1 and Mechanisms Underlying Its Secretion. <i>J Diabetes.</i> 2016; <b>8</b>(6): 753–65. <a target=xrefwindow id=d20143e2185 href="http://www.ncbi.nlm.nih.gov/pubmed/27287542">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2188 href="https://doi.org/10.1111/1753-0407.12439">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d20143e2198 class=n-a></a>Portha B, Tourrel-Cuzin C, Movassat J: Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. <i>Exp Diabetes Res.</i> 2011; <b>2011</b>: 376509. <a target=xrefwindow id=d20143e2206 href="http://www.ncbi.nlm.nih.gov/pubmed/21716694">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2209 href="https://doi.org/10.1155/2011/376509">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2212 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3118608">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d20143e2221 class=n-a></a>Garber AJ: Incretin effects on β-cell function, replication, and mass: the human perspective. <i>Diabetes Care.</i> 2011; <b>34 Suppl 2</b>: S258–63. <a target=xrefwindow id=d20143e2229 href="http://www.ncbi.nlm.nih.gov/pubmed/21525465">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2232 href="https://doi.org/10.2337/dc11-s230">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2235 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3632189">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d20143e2244 class=n-a></a>Xu G, Kaneto H, Lopez-Avalos MD, <i> et al.</i>: GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. <i>Diabetes Res Clin Pract.</i> 2006; <b>73</b>(1): 107–10. <a target=xrefwindow id=d20143e2255 href="http://www.ncbi.nlm.nih.gov/pubmed/16406191">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2258 href="https://doi.org/10.1016/j.diabres.2005.11.007">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d20143e2267 class=n-a></a>Buteau J, Foisy S, Joly E, <i> et al.</i>: Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. <i>Diabetes.</i> 2003; <b>52</b>(1): 124–32. <a target=xrefwindow id=d20143e2278 href="http://www.ncbi.nlm.nih.gov/pubmed/12502502">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2281 href="https://doi.org/10.2337/diabetes.52.1.124">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d20143e2290 class=n-a></a>Yusta B, Baggio LL, Estall JL, <i> et al.</i>: GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. <i>Cell Metab.</i> 2006; <b>4</b>(5): 391–406.<a target=xrefwindow id=d20143e2301 href="http://www.ncbi.nlm.nih.gov/pubmed/17084712">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2304 href="https://doi.org/10.1016/j.cmet.2006.10.001">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d20143e2313 class=n-a></a>Tsunekawa S, Yamamoto N, Tsukamoto K, <i> et al.</i>: Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; <i>in vivo</i> and <i>in vitro</i> studies. <i>J Endocrinol.</i> 2007; <b>193</b>(1): 65–74. <a target=xrefwindow id=d20143e2331 href="http://www.ncbi.nlm.nih.gov/pubmed/17400804">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2334 href="https://doi.org/10.1677/JOE-06-0148">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d20143e2344 class=n-a></a>Buteau J: GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. <i>Diabetes Metab.</i> 2008; <b>34</b>(Suppl 2): S73–S77. <a target=xrefwindow id=d20143e2352 href="http://www.ncbi.nlm.nih.gov/pubmed/18640589">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2355 href="https://doi.org/10.1016/S1262-3636(08)73398-6">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d20143e2364 class=n-a></a>Cunha DA, Ladrière L, Ortis F, <i> et al.</i>: Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. <i>Diabetes.</i> 2009; <b>58</b>(12): 2851–62. <a target=xrefwindow id=d20143e2375 href="http://www.ncbi.nlm.nih.gov/pubmed/19720788">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2378 href="https://doi.org/10.2337/db09-0685">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2382 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2780890">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d20143e2391 class=n-a></a>Biden TJ, Boslem E, Chu KY, <i> et al.</i>: Lipotoxic endoplasmic reticulum stress, β cell failure, and type 2 diabetes mellitus. <i>Trends Endocrinol Metab.</i> 2014; <b>25</b>(8): 389–98. <a target=xrefwindow id=d20143e2402 href="http://www.ncbi.nlm.nih.gov/pubmed/24656915">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2405 href="https://doi.org/10.1016/j.tem.2014.02.003">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733314816"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2414 class=n-a></a>Arden C: A role for Glucagon-Like Peptide-1 in the regulation of β-cell autophagy. <i>Peptides.</i> 2018; <b>100</b>: 85–93. <a target=xrefwindow id=d20143e2422 href="http://www.ncbi.nlm.nih.gov/pubmed/29412836">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2425 href="https://doi.org/10.1016/j.peptides.2017.12.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733314816">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727343589"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2438 class=n-a></a>Zummo FP, Cullen KS, Honkanen-Scott M, <i> et al.</i>: Glucagon-Like Peptide 1 Protects Pancreatic β-Cells From Death by Increasing Autophagic Flux and Restoring Lysosomal Function. <i>Diabetes.</i> 2017; <b>66</b>(5): 1272–85. <a target=xrefwindow id=d20143e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/28232493">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2452 href="https://doi.org/10.2337/db16-1009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727343589">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d20143e2465 class=n-a></a>Lim SW, Jin L, Jin J, <i> et al.</i>: Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus. <i>Sci Rep.</i> 2016; <b>6</b>: 29921. <a target=xrefwindow id=d20143e2476 href="http://www.ncbi.nlm.nih.gov/pubmed/27436514">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2479 href="https://doi.org/10.1038/srep29921">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2483 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4951772">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727683544"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2493 class=n-a></a>Carlessi R, Chen Y, Rowlands J, <i> et al.</i>: GLP-1 receptor signalling promotes β-cell glucose metabolism <i>via</i> mTOR-dependent HIF-1α activation. <i>Sci Rep.</i> 2017; <b>7</b>(1): 2661. <a target=xrefwindow id=d20143e2507 href="http://www.ncbi.nlm.nih.gov/pubmed/28572610">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2511 href="https://doi.org/10.1038/s41598-017-02838-2">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2514 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5454020">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727683544">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d20143e2527 class=n-a></a>Cornu M, Modi H, Kawamori D, <i> et al.</i>: Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. <i>J Biol Chem.</i> 2010; <b>285</b>(14): 10538–45. <a target=xrefwindow id=d20143e2538 href="http://www.ncbi.nlm.nih.gov/pubmed/20145256">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2541 href="https://doi.org/10.1074/jbc.M109.091116">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2545 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2856261">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732708272"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2554 class=n-a></a>Rowlands J, Cruzat V, Carlessi R, <i> et al.</i>: Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells. <i>Peptides.</i> 2018; <b>100</b>: 140–9. <a target=xrefwindow id=d20143e2565 href="http://www.ncbi.nlm.nih.gov/pubmed/29412813">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2568 href="https://doi.org/10.1016/j.peptides.2017.11.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732708272">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731181390"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2581 class=n-a></a>Holman RR, Bethel MA, Mentz RJ, <i> et al.</i>: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(13): 1228–39. <a target=xrefwindow id=d20143e2592 href="http://www.ncbi.nlm.nih.gov/pubmed/28910237">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2595 href="https://doi.org/10.1056/NEJMoa1612917">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731181390">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726744841"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2608 class=n-a></a>Marso SP, Bain SC, Consoli A, <i> et al.</i>: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(19): 1834–44. <a target=xrefwindow id=d20143e2619 href="http://www.ncbi.nlm.nih.gov/pubmed/27633186">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2622 href="https://doi.org/10.1056/NEJMoa1607141">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726744841">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d20143e2635 class=n-a></a>Marso SP, Daniels GH, Brown-Frandsen K, <i> et al.</i>: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2016; <b>375</b>(4): 311–22. <a target=xrefwindow id=d20143e2646 href="http://www.ncbi.nlm.nih.gov/pubmed/27295427">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2649 href="https://doi.org/10.1056/NEJMoa1603827">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2653 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4985288">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d20143e2663 class=n-a></a>Pfeffer MA, Claggett B, Diaz R, <i> et al.</i>: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>N Engl J Med.</i> 2015; <b>373</b>(23): 2247–57. <a target=xrefwindow id=d20143e2674 href="http://www.ncbi.nlm.nih.gov/pubmed/26630143">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2677 href="https://doi.org/10.1056/NEJMoa1509225">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733957466"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2686 class=n-a></a>Ramracheya R, Chapman C, Chibalina M, <i> et al.</i>: GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca<sup>2+</sup> channels. <i>Physiol Rep.</i> 2018; <b>6</b>(17): e13852. <a target=xrefwindow id=d20143e2700 href="http://www.ncbi.nlm.nih.gov/pubmed/30187652">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2704 href="https://doi.org/10.14814/phy2.13852">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2707 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6125244">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733957466">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734369077"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2720 class=n-a></a>Zhang Y, Parajuli KR, Fava GE, <i> et al.</i>: GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. <i>Diabetes.</i> 2019; <b>68</b>(1): 34–44. <a target=xrefwindow id=d20143e2731 href="http://www.ncbi.nlm.nih.gov/pubmed/30389749">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2734 href="https://doi.org/10.2337/db18-0317">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2738 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6302540">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734369077">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d20143e2751 class=n-a></a>Hughes DS, Narendran P: Alpha cell function in type 1 diabetes. <i>Br J Diabetes.</i> 2014; <b>14</b>(2): 45. <a target=xrefwindow id=d20143e2759 href="https://doi.org/10.15277/bjdvd.2014.014">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d20143e2768 class=n-a></a>Moon JS, Won KC: Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block. <i>Diabetes Metab J.</i> 2015; <b>39</b>(1): 1–9. <a target=xrefwindow id=d20143e2776 href="http://www.ncbi.nlm.nih.gov/pubmed/25729706">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2779 href="https://doi.org/10.4093/dmj.2015.39.1.1">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2782 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4342530">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734866944"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2791 class=n-a></a>Scott RV, Bloom SR: Problem or solution: The strange story of glucagon. <i>Peptides.</i> 2018; <b>100</b>: 36–41. <a target=xrefwindow id=d20143e2799 href="http://www.ncbi.nlm.nih.gov/pubmed/29412829">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2802 href="https://doi.org/10.1016/j.peptides.2017.11.013">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2805 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5805853">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734866944">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737560687"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e2819 class=n-a></a>Gentilella R, Pechtner V, Corcos A, <i> et al.</i>: Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: Are they all the same? <i>Diabetes Metab Res Rev.</i> 2019; <b>35</b>(1): e3070. <a target=xrefwindow id=d20143e2830 href="http://www.ncbi.nlm.nih.gov/pubmed/30156747">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2833 href="https://doi.org/10.1002/dmrr.3070">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737560687">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d20143e2846 class=n-a></a>Nuffer WA, Trujillo JM: Liraglutide: A New Option for the Treatment of Obesity. <i>Pharmacotherapy.</i> 2015; <b>35</b>(10): 926–34. <a target=xrefwindow id=d20143e2854 href="http://www.ncbi.nlm.nih.gov/pubmed/26497479">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2857 href="https://doi.org/10.1002/phar.1639">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d20143e2866 class=n-a></a>Graaf Cd, Donnelly D, Wootten D, <i> et al.</i>: Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. <i>Pharmacol Rev.</i> 2016; <b>68</b>(4): 954–1013. <a target=xrefwindow id=d20143e2877 href="http://www.ncbi.nlm.nih.gov/pubmed/27630114">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2880 href="https://doi.org/10.1124/pr.115.011395">Publisher Full Text </a> | <a target=xrefwindow id=d20143e2884 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5050443">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d20143e2893 class=n-a></a>Tang-Christensen M, Larsen PJ, Göke R, <i> et al.</i>: Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. <i>Am J Physiol.</i> 1996; <b>271</b>(4 Pt 2): R848–56. <a target=xrefwindow id=d20143e2904 href="http://www.ncbi.nlm.nih.gov/pubmed/8897973">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2907 href="https://doi.org/10.1152/ajpregu.1996.271.4.R848">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d20143e2916 class=n-a></a>Turton MD, O'Shea D, Gunn I, <i> et al.</i>: A role for glucagon-like peptide-1 in the central regulation of feeding. <i>Nature.</i> 1996; <b>379</b>(6560): 69–72. <a target=xrefwindow id=d20143e2927 href="http://www.ncbi.nlm.nih.gov/pubmed/8538742">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2930 href="https://doi.org/10.1038/379069a0">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d20143e2939 class=n-a></a>Burcelin R, Da Costa A, Drucker D, <i> et al.</i>: Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. <i>Diabetes.</i> 2001; <b>50</b>(8): 1720–8. <a target=xrefwindow id=d20143e2950 href="http://www.ncbi.nlm.nih.gov/pubmed/11473030">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2953 href="https://doi.org/10.2337/diabetes.50.8.1720">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d20143e2963 class=n-a></a>Athauda D, Foltynie T: The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: Mechanisms of action. <i>Drug Discov Today.</i> 2016; <b>21</b>(5): 802–18. <a target=xrefwindow id=d20143e2971 href="http://www.ncbi.nlm.nih.gov/pubmed/26851597">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2974 href="https://doi.org/10.1016/j.drudis.2016.01.013">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d20143e2983 class=n-a></a>Seufert J, Gallwitz B: The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. <i>Diabetes Obes Metab.</i> 2014; <b>16</b>(8): 673–88. <a target=xrefwindow id=d20143e2991 href="http://www.ncbi.nlm.nih.gov/pubmed/24373150">PubMed Abstract </a> | <a target=xrefwindow id=d20143e2994 href="https://doi.org/10.1111/dom.12251">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736855554"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3003 class=n-a></a>Grieco M, Giorgi A, Gentile MC, <i> et al.</i>: Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. <i>Front Neurosci.</i> 2019; <b>13</b>: 1112. <a target=xrefwindow id=d20143e3014 href="http://www.ncbi.nlm.nih.gov/pubmed/31680842">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3017 href="https://doi.org/10.3389/fnins.2019.01112">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3021 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6813233">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736855554">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731221371"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3034 class=n-a></a>Dhir G, Cusi K: Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: A novel therapeutic option. <i>J Investig Med.</i> 2018; <b>66</b>(1): 7–10. <a target=xrefwindow id=d20143e3042 href="http://www.ncbi.nlm.nih.gov/pubmed/28918389">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3045 href="https://doi.org/10.1136/jim-2017-000554">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731221371">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736065117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3058 class=n-a></a>Newsome P, Francque S, Harrison S, <i> et al.</i>: Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Aliment Pharmacol Ther.</i> 2019; <b>50</b>(2): 193–203. <a target=xrefwindow id=d20143e3069 href="http://www.ncbi.nlm.nih.gov/pubmed/31246368">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3072 href="https://doi.org/10.1111/apt.15316">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3076 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6617813">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736065117">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735913090"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3089 class=n-a></a>Jall S, Sachs S, Clemmensen C, <i> et al.</i>: Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. <i>Mol Metab.</i> 2017; <b>6</b>(5): 440–6. <a target=xrefwindow id=d20143e3100 href="http://www.ncbi.nlm.nih.gov/pubmed/28462078">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3103 href="https://doi.org/10.1016/j.molmet.2017.02.002">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3107 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5404097">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735913090">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732740978"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3121 class=n-a></a>Li T, Jiao J-J, Hölscher C, <i> et al.</i>: A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease. <i>Hippocampus.</i> 2018; <b>28</b>(5): 358–72. <a target=xrefwindow id=d20143e3132 href="http://www.ncbi.nlm.nih.gov/pubmed/29473979">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3135 href="https://doi.org/10.1002/hipo.22837">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732740978">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d20143e3148 class=n-a></a>Oben J, Morgan L, Fletcher J, <i> et al.</i>: Effect of the Entero-Pancreatic Hormones, Gastric Inhibitory Polypeptide and Glucagon-Like polypeptide-1(7–36) Amide, on Fatty Acid Synthesis in Explants of Rat Adipose Tissue. <i>J Endocrinol.</i> 1991; <b>130</b>(2): 267–72. <a target=xrefwindow id=d20143e3159 href="http://www.ncbi.nlm.nih.gov/pubmed/1919397">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3162 href="https://doi.org/10.1677/joe.0.1300267">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d20143e3171 class=n-a></a>Wang Y, Kole HK, Montrose-Rafizadeh C, <i> et al.</i>: Regulation of Glucose Transporters and Hexose Uptake in 3T3-L1 Adipocytes: Glucagon-Like peptide-1 and Insulin Interactions. <i>J Mol Endocrinol.</i> 1997; <b>19</b>(3): 241–8. <a target=xrefwindow id=d20143e3182 href="http://www.ncbi.nlm.nih.gov/pubmed/9460645">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3185 href="https://doi.org/10.1677/jme.0.0190241">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d20143e3194 class=n-a></a>Yang H, Egan JM, Wang Y, <i> et al.</i>: GLP-1 Action in L6 Myotubes Is Via a Receptor Different From the Pancreatic GLP-1 Receptor. <i>Am J Physiol</i> 1998; <b>275</b>(3): C675–C683. <a target=xrefwindow id=d20143e3205 href="http://www.ncbi.nlm.nih.gov/pubmed/9730951">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3208 href="https://doi.org/10.1152/ajpcell.1998.275.3.C675">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d20143e3217 class=n-a></a>Luque MA, González N, Márquez L, <i> et al.</i>: Glucagon-like peptide-1 (GLP-1) and Glucose Metabolism in Human Myocytes. <i>J Endocrinol.</i> 2002; <b>173</b>(3): 465–73. <a target=xrefwindow id=d20143e3228 href="http://www.ncbi.nlm.nih.gov/pubmed/12065236">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3231 href="https://doi.org/10.1677/joe.0.1730465">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d20143e3240 class=n-a></a>Perry T, Lahiri DK, Sambamurti K, <i> et al.</i>: Glucagon-like peptide-1 Decreases Endogenous Amyloid-Beta Peptide (Abeta) Levels and Protects Hippocampal Neurons From Death Induced by Abeta and Iron. <i>J Neurosci Res.</i> 2003; <b>72</b>(5): 603–12. <a target=xrefwindow id=d20143e3251 href="http://www.ncbi.nlm.nih.gov/pubmed/12749025">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3254 href="https://doi.org/10.1002/jnr.10611">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d20143e3264 class=n-a></a>Redondo A, Trigo MV, Acitores A, <i> et al.</i>: Cell Signalling of the GLP-1 Action in Rat Liver. <i>Mol Cell Endocrinol.</i> 2003; <b>204</b>(1–2): 43–50. <a target=xrefwindow id=d20143e3275 href="http://www.ncbi.nlm.nih.gov/pubmed/12850280">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3278 href="https://doi.org/10.1016/s0303-7207(03)00146-1">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d20143e3287 class=n-a></a>Gutzwiller JP, Tschopp S, Bock A, <i> et al.</i>: Glucagon-like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men. <i>J Clin Endocrinol Metab.</i> 2004; <b>89</b>(6): 3055–61. <a target=xrefwindow id=d20143e3298 href="http://www.ncbi.nlm.nih.gov/pubmed/15181098">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3301 href="https://doi.org/10.1210/jc.2003-031403">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d20143e3310 class=n-a></a>González N, Acitores A, Sancho V, <i> et al.</i>: Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. <i>Regul Pept.</i> 2005; <b>126</b>(3): 203–11. <a target=xrefwindow id=d20143e3321 href="http://www.ncbi.nlm.nih.gov/pubmed/15664668">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3324 href="https://doi.org/10.1016/j.regpep.2004.10.002">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d20143e3333 class=n-a></a>Gault VA, Hölscher C: GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. <i>Eur J Pharmacol.</i> 2008; <b>587</b>(1-3): 112–7. <a target=xrefwindow id=d20143e3341 href="http://www.ncbi.nlm.nih.gov/pubmed/18466898">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3344 href="https://doi.org/10.1016/j.ejphar.2008.03.025">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d20143e3353 class=n-a></a>Suarez-Pinzon WL, Power RF, Yan Y, <i> et al.</i>: Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. <i>Diabetes.</i> 2008; <b>57</b>(12): 3281–8. <a target=xrefwindow id=d20143e3364 href="http://www.ncbi.nlm.nih.gov/pubmed/18835930">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3367 href="https://doi.org/10.2337/db08-0688">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3371 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2584134">Free Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d20143e3380 class=n-a></a>Koehler JA, Baggio LL, Lamont BJ, <i> et al.</i>: Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. <i>Diabetes.</i> 2009; <b>58</b>(9): 2148–61. <a target=xrefwindow id=d20143e3391 href="http://www.ncbi.nlm.nih.gov/pubmed/19509017">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3394 href="https://doi.org/10.2337/db09-0626">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3398 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2731518">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1160337"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3408 class=n-a></a>Li Y, Perry T, Kindy MS, <i> et al.</i>: GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. <i>Proc Natl Acad Sci U S A.</i> 2009; <b>106</b>(4): 1285–90. <a target=xrefwindow id=d20143e3419 href="http://www.ncbi.nlm.nih.gov/pubmed/19164583">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3422 href="https://doi.org/10.1073/pnas.0806720106">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3426 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2633544">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1160337">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d20143e3439 class=n-a></a>Raab EL, Vuguin PM, Stoffers DA, <i> et al.</i>: Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. <i>Am J Physiol Regul Integr Comp Physiol.</i> 2009; <b>297</b>(6): R1785–94. <a target=xrefwindow id=d20143e3450 href="http://www.ncbi.nlm.nih.gov/pubmed/19846744">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3453 href="https://doi.org/10.1152/ajpregu.00519.2009">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3457 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2803622">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d20143e3466 class=n-a></a>Crajoinas RO, Oricchio FT, Pessoa TD, <i> et al.</i>: Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. <i>Am J Physiol Renal Physiol.</i> 2011; <b>301</b>(2): F355–63. <a target=xrefwindow id=d20143e3477 href="http://www.ncbi.nlm.nih.gov/pubmed/21593184">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3480 href="https://doi.org/10.1152/ajprenal.00729.2010">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d20143e3489 class=n-a></a>Hogan AE, Tobin AM, Ahern T, <i> et al.</i>: Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis. <i>Diabetologia.</i> 2011; <b>54</b>(11): 2745–54. <a target=xrefwindow id=d20143e3500 href="http://www.ncbi.nlm.nih.gov/pubmed/21744074">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3503 href="https://doi.org/10.1007/s00125-011-2232-3">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3507 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3188710">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d20143e3516 class=n-a></a>Li Y, Chigurupati S, Holloway HW, <i> et al.</i>: Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. <i>PLoS ONE.</i> 2012; <b>7</b>(2): e32008. <a target=xrefwindow id=d20143e3527 href="http://www.ncbi.nlm.nih.gov/pubmed/22384126">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3530 href="https://doi.org/10.1371/journal.pone.0032008">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3534 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3285661">Free Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d20143e3543 class=n-a></a>Foltynie T, Aviles-Olmos I: Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic. <i>Alzheimers Dement.</i> 2014; <b>10</b>(1 Suppl): S38–46. <a target=xrefwindow id=d20143e3551 href="http://www.ncbi.nlm.nih.gov/pubmed/24529524">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3554 href="https://doi.org/10.1016/j.jalz.2013.12.005">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d20143e3564 class=n-a></a>Faurschou A, Gyldenløve M, Rohde U, <i> et al.</i>: Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. <i>J Eur Acad Dermatol Venereol.</i> 2015; <b>29</b>(3): 555–9. <a target=xrefwindow id=d20143e3575 href="http://www.ncbi.nlm.nih.gov/pubmed/25139195">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3578 href="https://doi.org/10.1111/jdv.12629">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727879031"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3587 class=n-a></a>Athauda D, Maclagan K, Skene SS, <i> et al.</i>: Exenatide once weekly versus placebo in Parkinson's disease: A randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2017; <b>390</b>(10103): 1664–1675. <a target=xrefwindow id=d20143e3598 href="http://www.ncbi.nlm.nih.gov/pubmed/28781108">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3601 href="https://doi.org/10.1016/S0140-6736(17)31585-4">Publisher Full Text </a> | <a target=xrefwindow id=d20143e3605 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5831666">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727879031">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730126538"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3618 class=n-a></a>Mann JFE, Ørsted DD, Brown-Frandsen K, <i> et al.</i>: Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>N Engl J Med.</i> 2017; <b>377</b>(9): 839–48. <a target=xrefwindow id=d20143e3629 href="http://www.ncbi.nlm.nih.gov/pubmed/28854085">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3632 href="https://doi.org/10.1056/NEJMoa1616011">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730126538">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d20143e3645 class=n-a></a>Le Roux CW, Astrup A, Fujioka K, <i> et al.</i>: 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet.</i> 2017; <b>389</b>(10077): 1399–409. <a target=xrefwindow id=d20143e3656 href="http://www.ncbi.nlm.nih.gov/pubmed/28237263">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3659 href="https://doi.org/10.1016/S0140-6736(17)30069-7">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d20143e3668 class=n-a></a>Finan B, Ma T, Ottaway N, <i> et al.</i>: Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans. <i>Sci Transl Med.</i> 2013; <b>5</b>(209): 209ra151. <a target=xrefwindow id=d20143e3679 href="http://www.ncbi.nlm.nih.gov/pubmed/24174327">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3682 href="https://doi.org/10.1126/scitranslmed.3007218">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1165459"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3691 class=n-a></a>Day JW, Ottaway N, Patterson JT, <i> et al.</i>: A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. <i>Nat Chem Biol.</i> 2009; <b>5</b>(10): 749–57. <a target=xrefwindow id=d20143e3702 href="http://www.ncbi.nlm.nih.gov/pubmed/19597507">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3705 href="https://doi.org/10.1038/nchembio.209">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1165459">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d20143e3719 class=n-a></a>Thomas MK, Nikooienejad A, Bray R, <i> et al.</i>: 980-P: Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients. <i>Diabetes.</i> 2019; <b>68</b>(Supplement 1): 980–P. <a target=xrefwindow id=d20143e3730 href="https://doi.org/10.2337/db19-980-P">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725267777"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d20143e3739 class=n-a></a>Finan B, Yang B, Ottaway N, <i> et al.</i>: A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. <i>Nat Med.</i> 2015; <b>21</b>(1): 27–36. <a target=xrefwindow id=d20143e3750 href="http://www.ncbi.nlm.nih.gov/pubmed/25485909">PubMed Abstract </a> | <a target=xrefwindow id=d20143e3753 href="https://doi.org/10.1038/nm.3761">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725267777">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 06 Apr 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-239&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-239&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Institute of Life Science, Medical School, Swansea University, Swansea, Wales, SA2 8PP, UK<br/> <p> <div class=margin-bottom> Josh Reed <br/> <span>Roles: </span> Conceptualization, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Stephen C. Bain <br/> <span>Roles: </span> Funding Acquisition, Writing – Review & Editing </div> <div class=margin-bottom> Venkateswarlu Kanamarlapudi <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-239/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 06 Apr 2020, 9:239 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.20602.1">https://doi.org/10.12688/f1000research.20602.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Reed J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=22653 data-id=20602 data-downloads="" data-views="" data-scholar="10.12688/f1000research.20602.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-239/v1/pdf?article_uuid=83ae52c5-8505-438c-aac2-48d1c1d8abcd" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.20602.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Reed J, Bain SC and Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1 [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):239 (<a href="https://doi.org/10.12688/f1000research.20602.1" target=_blank>https://doi.org/10.12688/f1000research.20602.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=20602 id=mobile-track-article-signin-20602 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/20602?target=/articles/9-239"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=22653 /> <input name=articleId type=hidden value=20602 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>John P. Wilding</strong>, Obesity & Endocrinology Research Group, Institute of Ageing and Chronic Disease, University of Liverpool, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stephen Bloom</strong>, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 06 Apr 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-239&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-239&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=65693-61617></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=65694-61618></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-239/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>06 Apr 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>John P. Wilding</strong>, Obesity & Endocrinology Research Group, Institute of Ageing and Chronic Disease, University of Liverpool, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stephen Bloom</strong>, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-239&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-239/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding the role...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-239/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-239/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-239/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Reed J et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-239/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-239",
            templates : {
                twitter : "Recent advances in understanding the role of glucagon-like peptide.... Reed J et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-239/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding the role of glucagon-like peptide 1", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding the role of glucagon-like peptide 1", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/20602/22653")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "22653");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "61617": 0,
                           "61618": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "680d061a-40c1-47e5-9450-e0ea3a6fbecd";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-239.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-239.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-239.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-239.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-239.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>